So what you are saying is that the lenders who have filed their SC 13G's respectively they will be able to convert their Radient shares for Provista DX shares as the LOI was the intent between Provista and Radient in 2010..That is just one example..Keep researching..Especially RXPC pk....It is not just listings 8K' ..It is the fact that Radient has no $$ business and at any time they do not have to file..So Radient shares for Provista DX Shares...Thank you for your insights...That is very feasible you understand..Because we all know that Hedgies do not want to run this company, but to maintain enough shares and ownership so they can sell their share holdings when the Patents,merger, etc is finalized..They know they can;t get their investments back selling at .0001 .0002... You are correct about RXPC the lenders have already filed..Did you check out the SEC filings right before the lenders converted in 2012? I posted them here for you..Hope it helps you.. imo Radient Pharmaceuticals and Provista Life Sciences Announce New Blood Test for Lung Cancer Marketwire October 13, 2010: 08:45 AM ET
Provista Life Sciences and Radient Pharmaceuticals Corporation (RPC) (NYSE Amex: RPC) announced today the validation study results of a blood test for early detection of lung cancer and Provista's plans to broadly introduce this new test to market.
The study completed the requisite analyses and data evaluation needed to validate Provista's test, based on Radient Pharmaceutical Corporation's antigens for fibrinogen degradation products (FDP), successfully detects lung cancer with a high degree of accuracy. The study included men and women between 20-76 years of age. The data generated in this final study proved consistent with previous findings and produced positive clinical performance marks of 87% sensitivity; 95% specificity; and an ROC Accuracy of 0.97. By industry standards the study proved very successful and will serve as the cornerstone to Provista's efforts to introduce a new lung cancer detection assay branded LC Sentinel™ to market. Provista intends to introduce LC Sentinel™ as a CLIA Laboratory Developed Test (LDT) for use in high-risk lung cancer patient populations in the U.S. by the end of the fourth quarter 2010 through its standard clinical channels that include physicians, medical clinics and hospitals. The company expects to seek FDA registration for LC Sentinel™ in 2011.
According to Provista CEO William Gartner, "We are exceptionally pleased at the test results and will aggressively market and commercialize this important and potentially life-saving lung cancer test beginning in the fourth quarter 2010." Gartner also expressed high praise for the quality of the RPC's manufacturing facilities and chemicals indicating the Company is pleased to be an exclusive partner of RPC in the development of the test. In conjunction with today's announcement, RPC and Provista also announced the two Companies will execute an exclusive lab partnership agreement where Provista Life Sciences will purchase RPC reagents exclusively for the development of LC Sentinel™.
The American Cancer Society's estimates of the impact of lung cancer in the U.S. during 2009 include approximately 219,000 new cases (both non-small cell and small cell) and 159,000 deaths resulting from the disease, accounting for 28 percent of all cancer deaths. Lung cancer is the leading cause of cancer death among both men and women -- 62% of those diagnosed in late stages die within 5 years. Provista estimates there are approximately 18 million high-risk patients who stand to benefit from the test's US introduction.
According to Mr. Douglas MacLellan, Executive Chairman and CEO of RPC, "The detection benefit observed in this study represents a meaningful additional to tests available today. We are very encouraged by the potential benefit of this test to patients who are facing the deadly threat of lung cancer. As previously announced, RPC is actively engaged in acquisition negotiations with Provista and with the success of the deal; we expect to combine both companies to achieve a leadership presence in the global cancer diagnostics market."
On September 27, 2010 RPC signed an extension of its original agreement dated July 13, 2010 to merge with Provista Diagnostics Inc., making the agreement between Provista Diagnostics and Radient Pharmaceuticals effective through December 31, 2010. Both Companies have confirmed continued interest in the merger and to pursue completion of the deal within a timeframe that suits the needs of both Companies and shareholders.
Here is William explaining the Onko-Sure test and/or LC Sentinel. This was from mid 2013...So he did finalized the agreement with Radient He did have the money in 2012..
News 
Market Data 
Discover 
